Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Strasbourg, France
ClinicalTrials.gov Identifier:
NCT00412048
First received: December 14, 2006
Last updated: November 12, 2012
Last verified: November 2012

December 14, 2006
November 12, 2012
April 2012
February 2018   (final data collection date for primary outcome measure)
Comparing fMRI data between 3 groups of subjects: MCI, Alzheimer's disease and normal subjects [ Time Frame: 1, 5 years ] [ Designated as safety issue: No ]
Comparing fMRI data between 3 groups of subjects : MCI, Alzheimer’s disease and normal subjects
Complete list of historical versions of study NCT00412048 on ClinicalTrials.gov Archive Site
Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer's disease [ Time Frame: Prediction of Alzheimer's disease on fMRI data ] [ Designated as safety issue: No ]
Follow-up of MCI patients at 6, 12 and 18 months to detect a conversion to Alzheimer’s disease
Not Provided
Not Provided
 
Functional Magnetic Resonance Imaging - Synthetic Aperture Magnetometry (fMRI-SAM) and Alzheimer's Disease
Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.

The aim of the protocol is to study the resting brain activation profile of 3 groups of people, using a new fMRI procedure, called fMRI-SAM. fMRI-SAM will be applied to 25 Alzheimer's disease (AD) patients, 25 patients suffering from amnestic - mild cognitive impairment (MCI) - a clinical picture which may be a prodromal form of AD - and 60 healthy controls. The first analysis of the data will search differences of brain activation profiles between the 3 groups. In the second step, the investigators will study the predictive value of fMRI-SAM to detect MCI patients who will later convert to AD.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Alzheimer's Disease
Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
There is a fMRI to be realized in the 3 arms. No drug is administered
  • ALZHEIMER DISEASE
    Intervention: Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
  • MOLD COGNITIVE IMPAIRMENT
    Intervention: Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
  • CONTROLS
    Intervention: Procedure: fMRI to detect MCI patients who will convert to Alzheimer's disease
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
February 2018
February 2018   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Alzheimer's disease of mild to moderate severity (25 patients)
  • Amnestic MCI patients (25 patients)
  • 55-75 year-old patients

Exclusion criteria:

  • Any other cause of dementia for AD patients
  • Any stroke
  • Any disease with a negative vital prognosis
Both
55 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00412048
3659
No
University Hospital, Strasbourg, France
University Hospital, Strasbourg, France
Not Provided
Principal Investigator: Francois Sellal, MD Hôpitaux Universitaires de Strasbourg
University Hospital, Strasbourg, France
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP